Establish the First International Database on Semi-quantitative Values Obtained in Scintigraphy With Datscan® in Cadmium-Zinc-Telluride (CZT) Camera (VERITON-CT)

Datscan scintigraphy is a nuclear medicine examination allowing the diagnosis of neurodegenerative pathologies linked to damage to dopaminergic pathways, such as Parkinson's disease (essential for the differential diagnosis of essential tremor).

开始日期2025-04-30

申办/合作机构

Centre Hospitalier Regional de Nancy

CTR20201646

/ Completed临床1期

一项在中国健康志愿者中评估单剂量DaTSCAN碘[123I]氟潘注射液的安全性、生物分布和内辐射剂量的1期非随机、非比较性、开放性研究

经过与药品审评中心的沟通交流，进行一项在中国健康志愿者中评估单剂量DaTSCAN碘[123I]氟潘注射液的安全性、生物分布和内辐射剂量的1期非随机、非比较性、开放性研究

开始日期2021-05-14

申办/合作机构

GE Healthcare B.V.

[+2]

NCT04564092

/ Completed临床1期

A Phase 1, Non-randomised, Noncomparative, Open-label Study to Assess the Safety, Biodistribution, and Internal Radiation Dosimetry of a Single Dose of DaTSCAN™ Ioflupane (123I) Injection in Chinese Healthy Volunteers

This is a phase 1, single-centre, single-group, nonrandomized, noncomparative, open-label, single-dose study to evaluate the safety, biodistribution, internal radiation dosimetry, and effective dose of DaTSCAN™ ioflupane (123I) injection in Chinese Healthy Volunteers.

开始日期2021-05-13

申办/合作机构

GE Healthcare Holdings, Inc.

[+1]

100 项与碘[123I]氟潘相关的临床结果

登录后查看更多信息

100 项与碘[123I]氟潘相关的转化医学

登录后查看更多信息

100 项与碘[123I]氟潘相关的专利（医药）

登录后查看更多信息

384

项与碘[123I]氟潘相关的文献（医药）

2025-03-01·Brain Disorders

A proposal of visual assessment of serotonergic deficits in parkinsonian syndromes: An 123I-FP-CIT SPECT study

作者: Oizumi, Hideki ; Sugimura, Yoko ; Tanaka, Hiroyasu ; Baba, Toru ; Yoshioka, Masaru ; Takeda, Atsushi ; Totsune, Tomoko ; Takahashi, Toshiaki ; Nagamatsu, Ken-ichi

¹²³I-FP-CIT, primarily used for imaging dopamine transporters in the nigrostriatal pathway, also shows some affinity for the serotonin transporter (SERT), which is predominantly distributed in the raphe nuclei in the brainstem.Recent imaging studies have demonstrated that compared with Parkinson′s disease (PD), atypical parkinsonian syndromes (PS) exhibit pronounced SERT reduction using semiquant. methods.However, the utility of qual. visual assessment methods for SERT has been poorly discussed to date.The aims of this study were to propose a visual assessment grading system of brainstem ¹²³I-FP-CIT uptake and investigate the ability of this method to differentiate PD from PS.We analyzed the imaging data of 97 parkinsonian patients who underwent ¹²³I-FP-CIT SPECT.First, we graded ¹²³I-FP-CIT uptake in the midbrain and pons with a 4-degree scale and analyzed the interrater agreement of our grading method.Next, we compared the visual grading data of the PD (n = 59) and PS (n = 11) groups and analyzed the diagnostic utility of the qual. visual assessment method.The interrater agreement of the visual grading of ¹²³I-FP-CIT uptake among the three raters was moderate (Fleiss′ Kappa 0.480 for midbrain, 0.488 for pons).The patterns of ¹²³I-FP-CIT uptake in the pons differed significantly between patients with PD and PS (p = 0.035).The visual assessment-based classification showed 81.8 % sensitivity, 61.0 % specificity, 28.1 % pos. predictive value, and 94.7 % neg. predictive value in distinguishing PS from PD.Visual assessment of SERT abnormalities with ¹²³I-FP-CIT may contribute to differentiating PD and PS in clin. settings.

2025-02-01·Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)

Justification and impact of SPECT ¹²³I-FP-CIT use in the differential diagnosis and management of movement disorders (MD) in a national referral hospital

Article

作者: Canales Rodríguez, L ; Ruiz Solís, S ; Mitjavila Casanovas, M

¹²³I-FP-CIT SPECT is a key tool in the differential diagnosis of movement disorders (MD), but its appropriate indication is essential to optimize resources and avoid unnecessary tests.AIMTo evaluate the adequacy and impact of ¹²³I-FP-CIT SPECT in the diagnosis and management of MD according to clinical guidelines.PATIENTS AND METHODSRetrospective study involving 249 patients with suspected parkinsonism (PK) of uncertain origin. All underwent ¹²³I-FP-CIT SPECT and had a clinical follow-up of exceeding 12 months. Requests were classified based on their adherence to clinical guidelines. Variables analyzed included sex, age, justification for the request, management after SPECT, and final diagnosis.RESULTS91.57% of the requests were appropriate, while 8.43% did not adhere to the guidelines. Diagnosis changed in 48.6% of cases and management in 70.68% after the scan, especially in inconclusive cases and initiation of therapy. General neurologists evaluated more cases and made more appropriate requests (96.3% vs 76.67%; p < 0.001). However, MD specialists, despite less appropriate use of the guidelines, achieved a higher number of conclusive diagnoses in complex cases.CONCLUSION¹²³I-FP-CIT SPECT has significant clinical impact when used in accordance with clinical guidelines, improving the diagnosis and management of MD. Unjustified scans reduce its utility. Collaboration between general neurologists and MD specialists is fundamental; the latter, although showing less adherence to guidelines in requesting the test, achieve a higher number of conclusive diagnoses in complex cases.

2025-01-01·Japanese Journal of Radiology

Comparison of the ability of different quantitative indices in 123I-FP-CIT single-photon emission computed tomography to differentiate dopaminergic neurodegenerative disease

Article

作者: Shimada, Naokazu ; Sato, Tomohiro ; Sawai, Setsu

AbstractPurposeBy imaging dopamine transporter (DAT) uptake in the striatum, 123I-FP-CIT SPECT can differentiate dopaminergic neurodegenerative disease (dNDD) and non-dNDD, which differ in pathophysiology and clinical management. Our aim was to compare and validate the diagnostic abilities of various 123I-FP-CIT SPECT quantitative indices for dNDD.Materials and methodsDistribution volume ratio (DVR) and binding ratio (BR), measures of DAT uptake capacity, were measured by analyzing clinical 123I-FP-CIT SPECT images of 29 patients with dNDD, including dementia with Lewy bodies and Parkinson’s disease, and 18 patients with non-dNDD, using Montreal Neurological Institute space-based anatomical standardization and an atlas template, which utilizes statistical parametric mapping. Additionally, we computed the specific binding ratio (SBR) based on Bolt’s method and the maximum and mean standardized uptake values (SUVmax and SUVmean, respectively).ResultsThe caudate-to-occipital lobe, putamen-to-occipital lobe, and striatum-to-occipital lobe ratios (COR, POR, and SOR, respectively) on DVR and POR and SOR on BR were significantly lower in dNDD than in non-dNDD, with areas under the ROC curve (AUCs) of 0.941–0.960, showing high diagnostic accuracy for dNDD. However, the AUC of COR on BR was 0.839, indicating lower diagnostic performance. SBR had an AUC of 0.921, while SUVmax and SUVmean had AUCs of 0.906 and 0.900, respectively. Although striatal asymmetry on both DVR and BR exhibited AUCs of 0.728 and 0.734 and asymmetry on SBR showed an AUC of 0.757, the ratio-based DAT quantitative indices were superior. There were strong positive correlations of DVR with BR, DVR with SBR or SUVmax, BR with SBR or SUVmax, and SBR with SUVmax.ConclusionCOR, POR, and SOR on DVR and POR and SOR on BR were the most useful DAT quantitative indices. These indices can be compared with SBR and SUV, suggesting that comprehensive evaluation improves the diagnostic accuracy of dNDD.

项与碘[123I]氟潘相关的新闻（医药）

2025-03-30

·SYNAPSE

GE HealthCare Completes Acquisition of Nihon Medi-Physics (NMP), a Leading Radiopharmaceutical Company in Japan

GE HealthCare has completed its acquisition of Sumitomo Chemical’s 50% stake in Nihon Medi-Physics (NMP), giving it full ownership. As part of GE HealthCare, NMP, already a leading radiopharmaceutical company in Japan, is positioned to enhance patient access to next-generation radiopharmaceuticals that enable detection and diagnosis of disease. CHICAGO--(BUSINESS WIRE)--Mar. 31, 2025-- GE HealthCare Technologies Inc. (GE HealthCare or the Company) (Nasdaq: GEHC) has completed its acquisition of the remaining 50% stake in Nihon Medi-Physics Co., Ltd (NMP), from Sumitomo Chemical, giving it full ownership. As part of GE HealthCare, NMP can further build on its expertise in developing and manufacturing proprietary and in-licensed radiopharmaceuticals used in single photon emission computed tomography (SPECT) and positron emission tomography (PET) molecular imaging procedures to detect and diagnose disease. Kevin O’Neill, President & CEO of GE HealthCare’s Pharmaceutical Diagnostics (PDx) segment, who will also become President of NMP, said: “We are delighted to welcome Nihon Medi-Physics to GE HealthCare, increasing our existing footprint and offering in Japan, where our contrast media and medical devices are used every day to enable imaging procedures across the country. Japan is on a path to becoming a leader in the $7 billion molecular imaging global market and a center of excellence for Asian markets. As part of GE HealthCare, NMP will play a key role in that journey, including bringing its deep expertise and scale to global innovators looking to bring next-generation radiopharmaceuticals to the Japan market and beyond.” NMP’s product portfolio includes GE HealthCare radiopharmaceuticals used to enable molecular imaging across neurology, cardiology and oncology procedures. NMP, headquartered in Tokyo, was formed in 1973 and generated revenues of 28.2B JPY (~$183M) in 2023. GE HealthCare acquired Amersham plc in 2004, and subsequently held a 50% stake in NMP. The Company expects this transaction to be neutral to Adjusted EPS in year one and accretive thereafter.

并购诊断试剂

2025-02-06

·化学经纬

书籍分享||新药化学全合成路线手册

内容介绍本书归纳和综述了新药的化学合成路线。覆盖范围为近5年美国FDA批准上市的新分子实体药共109个。针对每一个药物，本书给出了药物简介，药物化学结构信息，产品上市信息，药品专利保护和市场独占权保护信息，化学全合成路线和参考文献等。这些合成路线大多是目前制药工业中正在使用的化学合成工艺，有较高的实用性和学术价值。对参与反应的起始原料、中间体、反应产物都给出了详细的化学结构。每一步化学合成反应都给出了重要的化学试剂、催化剂、所使用的溶剂、合成反应条件及文献出处等。本书的特点是：作者从浩如烟海的科技文献中，精心挑选出最新、最有实用价值的合成方法，汇编成化学合成路线图，内容简洁，深入浅出，逻辑性强，容易理解，以最少的篇幅表达最多的技术信息，可帮助读者很快找到他们需要的药物合成方法及最可靠的原始科学论文。读者对象： 1.任何从事与化学合成、药物合成、精细化工相关专业的科研人员、企业管理人员。 2.有机化学专业、药学专业、生物制药专业等大专院校的高年级学生、研究生、教师及科研人员。 3.从事客户委托的药物原料与药物中间体合成的科研人员、企业管理人员。编辑推荐对于制药企业而言,一个好的药物全合成路线, 可以大大缩短生产周期,简化生产工艺,降低生产成本,节约能源,减少或消除对环境的化学污染与排放。本书为了顺应我国近年来生物制药及医药工业飞速发展的潮流编写的，详细介绍了近五年美国FDA批准上市的所有（109个）新分子实体药的化学全合成路线。这些全合成路线多数是国外制药厂目前正在使用的工艺，其经济效益及社会效益都是极为显著，因此本书既有较高的科学价值又有很大的实用性。作者简介陈清奇，旅美药学家和化学家，担任美国MedKoo生物医药科研公司总裁，同时兼任美国数家生物制药公司的技术顾问，中国国内数个大学的客座教授。研究领域为药物化学，纳米医学体外诊断技术。书籍目录 Abiraterone Acetate（醋酸阿比特龙）001 Aclidinium Bromide（阿克利溴铵）006 Afatinib（阿法替尼）009 Alcaftadine（阿卡他定）014 Alogliptin（阿格列汀）017 Apixaban（阿哌沙班）022 Apremilast（阿普斯特）028 Avanafil（阿伐那非）033 Axitinib（阿西替尼）038 Azilsartan Kamedoxomil（阿齐沙坦酯钾盐）044 Bazedoxifene（巴多昔芬）048 Bedaquiline（贝达喹啉）053 Belinostat（贝利司他）060 Boceprevir（波西普韦）064 Bosutinib（博舒替尼）071 Cabozantinib（卡博替尼）075 Canagliflozin（卡格列净）078 Carfilzomib（卡非佐米）083 Ceftaroline Fosamil（头孢洛林酯）087 Ceftolozane（噻呋特啰嗪）094 Ceritinib（色瑞替尼）098 Clobazam（氯巴占）101 Cobicistat（可比司他）104 Crizotinib（克里唑蒂尼）112 Dabigatran Etexilate Mesylate（甲磺酸达比加群酯）118 Dabrafenib（达拉菲尼）123 Dapagliflozin（达格列净）127 Dasabuvir（达沙布韦）132 Deferiprone（去铁酮）136 Dienogest（地诺孕素）138 Dolutegravir（度鲁特韦）141 Droxidopa（屈昔多巴）145 Efinaconazole（艾氟康唑）149 Eliglustat（依利格鲁司特）152 Elvitegravir（埃替格韦）155 Empagliflozin（依帕列净）161 Enzalutamide（恩杂鲁胺）166 Eribulin Mesylate（甲磺酸艾日布林）168 Eslicarbazepine Acetate（艾利西平醋酸酯）175 Estradiol Valerate（雌二醇戊酸酯）180 Ezogabine（依佐加滨）185 Finafloxacin（非那沙星）193 Fingolimod Hydrochloride（盐酸芬戈莫德）197 Florbetapir F 18（氟比他匹）205 Flutemetamol F 18（富特米他）211 Gabapentin Enacarbil（加巴喷丁恩那卡比）214 Gadobutrol（钆布醇）218 Gadoterate Meglumine（钆特酸葡甲胺）224 Ibrutinib（依鲁替尼）227 Icatibant（艾替班特）232 Idelalisib（艾代拉里斯）234 Indacaterol （茚达特罗）236 Ingenol Mebutate（巨大戟醇甲基丁烯酸酯）240 Ioflupane 123I（碘[123I]氟潘）242 Ivacaftor（依瓦卡特）247 Ledipasvir（雷迪帕韦）250 Linaclotide（利那洛肽）259 Linagliptin（利拉利汀）261 Lomitapide（洛美他派）267 Lorcaserin（氯卡色林）270 Lucinactant（芦西纳坦）274 Luliconazole（卢立康唑）276 Lurasidone（鲁拉西酮）279 Macitentan（马西替坦）283 Miltefosine（米替福新）286 Mipomersen Sodium（米泊美生钠）290 Mirabegron（米拉贝隆）292 Naloxegol（纳罗克格）296 Netupitant（奈妥吡坦）299 Nintedanib（尼达尼布）303 Olaparib（奥拉帕尼）307 Olodaterol（奥达特罗）311 Omacetaxine Mepesuccinate（高三尖杉酯碱）315 Ombitasvir（艾姆伯韦）319 Ospemifene（奥培米芬）323 Paritaprevir（帕瑞它韦）327 Pasireotide（帕瑞肽）331 Peramivir（帕拉米韦）333 Perampanel（吡仑帕奈）337 Pirfenidone（吡非尼酮）343 Pomalidomide（泊马度胺）345 Ponatinib（泊那替尼）351 Regorafenib（瑞戈非尼）355 Rilpivirine（利匹韦林）357 Riociguat（利奥西呱）366 Rivaroxaban（利伐沙班）370 Roflumilast（罗氟司特）378 Ruxolitinib（鲁索替尼）384 Simeprevir（司美匹韦）388 Sofosbuvir（索非布韦）396 Suvorexant（苏沃雷生）401 Tafluprost（他氟前列腺素）405 Tasimelteon（他司美琼）409 Tavaborole（它瓦波罗）413 Tedizolid Phosphate（磷酸特地唑胺）415 Telaprevir（替拉瑞韦）418 Teriflunomide（特立氟胺）426 Ticagrelor（替格瑞洛）430 Tofacitinib（托法替尼）438 Trametinib（曲美替尼）443 Umeclidinium（芜地溴铵）447 Vandetanib（凡德他尼）450 Vemurafenib（威罗菲尼）456 Vilanterol（维兰特罗）460 Vilazodone Hydrochloride（盐酸维拉佐酮）463 Vismodegib（维莫德吉）468 Vorapaxar（沃拉帕沙）470 Vortioxetine（沃替西汀）473 附录1本书使用的期刊名称缩写表477 附录2专利文献代码481 附录3美国药品专利中的用途代码定义484 附录4美国药品市场独占权代码定义530 附录5美国FDA于2010—2014批准上市的药物名单563 英文索引607 中文索引611 CAS登记号索引613 下载方式现在，这份资料分享给大家。小编在公众号设置了自动回复功能，在公众号后台回复关键词：新药全合成 ●书籍分享||有机氧化反应原理与应用 ●书籍分享||有机卤化反应原理及应用 ●推荐合成书籍【有机缩合反应原理与应用】 ●推荐合成书籍【有机环合反应原理与应用】 ●书籍分享||有机还原反应原理与应用 ●ChemDraw使用让你从化学菜鸟变成老鸟 ●干货分享||有机合成: 策略与控制 ●干货分享||有机合成工艺研发-副反应抑制法 ●基础有机化学(邢其毅)第3、4版教材+习题解析 ●ChemDrawV20最新版详细安装图文教程 ●干货分享||核磁共振二维谱 ●书籍分享||全合成中的经典:更多的目标、战略和方法 ●书籍分享||实用药物化学 ●书籍分享||基于模仿创新的小分子药物发明 ●书籍分享||制药工艺开发-目前的化学与工程挑战 ●书籍分享||手性合成:不对称反应及其应用(第5版) ●书籍分享||新药研发案例研究--明星药物如何从实验室走向市场 ●书籍分享||英汉·汉英化学化工词汇 ●书籍分享||有机化学结构与功能（第四版） ●书籍分享||过渡金属有机化学(原著第6版） ●重磅书籍分享||不对称催化基础 ●书籍分享||药物设计学-唐赟

上市批准高管变更

2024-11-30

·SYNAPSE

GE HealthCare to Acquire Remaining 50% Stake in Nihon Medi-Physics (NMP), a Leading Radiopharmaceutical Company in Japan, from Sumitomo Chemical

CHALFONT ST GILES, England--([BUSINESS WIRE](https://www.businesswire.com/))--GE HealthCare (Nasdaq: GEHC) has agreed to acquire full ownership of Nihon Medi-Physics Co., Ltd (NMP), by purchasing from Sumitomo Chemical (TYO: 4005) the 50% stake it does not already own. As part of GE HealthCare, NMP can build on its expertise developing and manufacturing proprietary and in-licensed radiopharmaceuticals used in single photon emission computed tomography (SPECT) and positron emission tomography (PET) molecular imaging procedures to detect and diagnose disease. Sumitomo and GE HealthCare expect the agreement to close in early 2025, subject to regulatory approvals. NMP’s product portfolio includes GE HealthCare radiopharmaceuticals used to enable clinical images across neurology, cardiology and oncology procedures, such as its amyloid visualization radiotracer, VIZAMYL® Injection (Flutemetamol (18F) Injection), used in the Alzheimer’s pathway; DaTSCAN® Injection (Ioflupane (¹²³I) injection) used to evaluate patients with suspected Parkinson’s Disease or Dementia with Lewy Bodies; and MYOVIEW® (Technetium (99mTc) Tetrofosmin), used in SPECT myocardial perfusion imaging for the evaluation of known or suspected coronary artery disease. NMP, headquartered in Tokyo, was formed in 1973 and generated revenues of 28.2B JPY (~$183M) in 2023. In addition to 13 manufacturing facilities, NMP also focuses on research and development, including nonclinical and clinical development of radiotracers and theranostics research. GE HealthCare has held its 50% stake in NMP since acquiring Amersham plc in 2004 and holds three positions on its Board of Directors. Kevin O’Neill, President & CEO of the Pharmaceutical Diagnostics (PDx) segment of GE HealthCare, said: “As the third largest pharmaceutical market in the world1, and amongst the leading countries by number of cyclotrons2, Japan is on a path to becoming a leader in the $7 billion molecular imaging global market and a center of excellence for Asian markets. NMP will play a key role in that journey, including bringing its deep expertise and scale to global innovators looking to bring novel products to the Japan market and beyond. This will strengthen our precision care strategy in Asia and our existing footprint in Japan, where our contrast media and medical devices are used every day to enable imaging procedures across the country.” Hiroshi Ueda, Executive Vise President, Sumitomo Chemical, said: “We are proud of our 50-year relationship with NMP and our partnership with GE HealthCare to ensure patients in Japan could benefit from access to molecular imaging. At a time of exciting developments in the industry, following its discussions with Sumitomo Chemical, we believe GE HealthCare is the best owner to enable NMP to continue its successful growth journey. I would like to recognize NMP’s leadership and talented team for their significant achievements to date and their commitment to patients.” As a leading global medical technology and pharmaceutical diagnostics innovator, GE HealthCare provides both molecular imaging equipment and proprietary radiotracers used across major patient care areas. The recent U.S. FDA approval of GE HealthCare’s first-of-its-kind PET radiopharmaceutical, Flyrcado™ (flurpiridaz F 18 injection), its in-licensing of Phase II FAPI assets and broadening theranostics offerings are all examples of the company’s commitment to novel diagnostics that are shaping the future of molecular imaging to drive improved patient outcomes. GE HealthCare’s PDx segment is a global leader in imaging agents used to support over 120 million patient procedures per year globally, equivalent to four patient procedures every second. The Company expects this transaction to be neutral to Adjusted EPS3,4 in year one and accretive thereafter. GE HealthCare was advised by Solomon Partners Securities, LLC. **Forward-Looking Statements** This release contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as “will,” “expect,” “may,” “would,” “could,” “plan,” “believe,” “anticipate,” “intend,” “estimate,” “potential,” “position,” “forecast,” “target,” “guidance,” “outlook,” and similar expressions. These forward-looking statements may include, but are not limited to, statements about the transaction, the completion and expected results of the transaction, and GE HealthCare Technologies Inc.’s (the “Company’s”) performance, growth opportunities, and strategy. These forward-looking statements involve risks and uncertainties, many of which are beyond the control of the Company. Factors that could cause the Company’s actual results to differ materially from those described in its forward-looking statements include, but are not limited to, the conditions to the completion of the transaction may not be satisfied; closing of the transaction may not occur or may be delayed; the Company may be unable to achieve the anticipated benefits of the transaction; operating costs and business disruptions (including, without limitation, difficulties in maintaining relationships with employees, customers, and suppliers) may be greater than expected; the Company may assume unexpected risks and liabilities; and completing the transaction may distract the Company’s management from other important matters. Other factors that may cause such a difference also include those discussed in the "Risk Factors" section of the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission and any updates or amendments it makes in future filings. There may be other factors not presently known to the Company or which it currently considers to be immaterial that could cause the Company’s actual results to differ materially from those projected in any forward-looking statements the Company makes. The Company does not undertake any obligation to update or revise its forward-looking statements except as required by applicable law or regulation. **About GE HealthCare Technologies Inc.** GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $19.6 billion business with approximately 51,000 colleagues working to create a world where healthcare has no limits. Follow us on [LinkedIn](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fgehealthcare&esheet=54159612&newsitemid=20241201060498&lan=en-US&anchor=LinkedIn&index=1&md5=8b71aacc0c8a28615a479f49839b2367), [X](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fx.com%2FGEHealthCare&esheet=54159612&newsitemid=20241201060498&lan=en-US&anchor=X&index=2&md5=5d3e010c5b6762aa437c9ed721a93fae), [Facebook](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.facebook.com%2FGEHealthCare%2F&esheet=54159612&newsitemid=20241201060498&lan=en-US&anchor=Facebook&index=3&md5=afb7811bf3d186531a1f0195046c19a3), [Instagram](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.instagram.com%2Fgehealthcare%2F&esheet=54159612&newsitemid=20241201060498&lan=en-US&anchor=Instagram&index=4&md5=3e9a372d9f56b271b045aed2f9b1ed7e), and [Insights](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.gehealthcare.com%2Finsights&esheet=54159612&newsitemid=20241201060498&lan=en-US&anchor=Insights&index=5&md5=528c8409aca3aa77dc9faa2bd39a47a3) for the latest news, or visit our website [https://www.gehealthcare.com](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.gehealthcare.com%2F&esheet=54159612&newsitemid=20241201060498&lan=en-US&anchor=https%3A%2F%2Fwww.gehealthcare.com&index=6&md5=149ee377d64e90ca25044fcc3fff9335) for more information. 1 [https://www.trade.gov/country-commercial-guides/japan-pharmaceuticals](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.trade.gov%2Fcountry-commercial-guides%2Fjapan-pharmaceuticals&esheet=54159612&newsitemid=20241201060498&lan=en-US&anchor=https%3A%2F%2Fwww.trade.gov%2Fcountry-commercial-guides%2Fjapan-pharmaceuticals&index=7&md5=469d2d595d8ea2691b2fbf21839f9df1), accessed on October 29, 2024 2 [https://nucleus.iaea.org/sites/accelerators/Pages/Cyclotron.aspx](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fnucleus.iaea.org%2Fsites%2Faccelerators%2FPages%2FCyclotron.aspx&esheet=54159612&newsitemid=20241201060498&lan=en-US&anchor=https%3A%2F%2Fnucleus.iaea.org%2Fsites%2Faccelerators%2FPages%2FCyclotron.aspx&index=8&md5=2bd260a4b0f14e662995bcc8256bab6e), accessed on October 29, 2024 3 See our latest [earnings release](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Finvestor.gehealthcare.com%2Fnode%2F10446%2Fpdf&esheet=54159612&newsitemid=20241201060498&lan=en-US&anchor=earnings+release&index=9&md5=200cc703972627cdc567e9acdbf69787) dated October 30, 2024 for the definition of Adjusted EPS. 4 Non-GAAP financial measure

并购上市批准

100 项与碘[123I]氟潘相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10014	碘[123I]氟潘	V09AB03	DB08824

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
路易体病	美国	GE Healthcare, Inc.	2022-11-01
帕金森病	加拿大	GE Healthcare Canada, Inc.	2017-12-07
诊断试剂	日本	Nihon Medi-Physics Co., Ltd.	2013-09-20
帕金森障碍	冰岛	GE Healthcare B.V.	2000-07-27
帕金森障碍	列支敦士登	GE Healthcare B.V.	2000-07-27
帕金森障碍	挪威	GE Healthcare B.V.	2000-07-27
帕金森障碍	欧盟	GE Healthcare B.V.	2000-07-27

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
多系统萎缩	临床前	中国	通用电气药业（上海）有限公司	2020-06-28
多系统萎缩	临床前	中国	GE Healthcare B.V.	2020-06-28
多系统萎缩	临床前	中国	GE Healthcare Pvt Ltd.	2020-06-28
进行性核上性麻痹	临床前	中国	通用电气药业（上海）有限公司	2020-06-28
进行性核上性麻痹	临床前	中国	GE Healthcare Pvt Ltd.	2020-06-28
进行性核上性麻痹	临床前	中国	GE Healthcare B.V.	2020-06-28
进行性核上性麻痹	临床前	中国	GE Healthcare Holdings, Inc.	2020-06-28
阿尔茨海默症	临床前	德国	GE Healthcare Holdings, Inc.	2003-11-01
血管性痴呆	临床前	德国	GE Healthcare Holdings, Inc.	2003-11-01
路易体病	临床前	德国	GE Healthcare Holdings, Inc.	2003-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


EANM2024	N/A	帕金森障碍	485	123I-Ioflupane (Standard-dose group)	鏇艱淵網構壓餘艱觸範(襯廠網積餘簾糧糧鑰構) = 選醖獵鹽蓋壓鏇鬱糧窪廠遞選遞構範餘蓋獵選 (積顧窪積製蓋糧衊簾壓 )	不佳	2024-09-27
				123I-Ioflupane (Half-dose group)	鏇艱淵網構壓餘艱觸範(襯廠網積餘簾糧糧鑰構) = 壓膚廠構鹽顧築遞構廠廠遞選遞構範餘蓋獵選 (積顧窪積製蓋糧衊簾壓 )
P8-4.001 (AAN2024)	N/A	-	270	[123I] Ioflupane (African Americans)	網襯蓋築選獵廠網築積(範淵衊願夢憲顧餘構鹹): P-Value = 0.002 更多	-	2024-04-09
				[123I] Ioflupane (Caucasians)
NCT04193527 (CTgov)	临床3期	特发性震颤 \| 进行性核上性麻痹 \| 多系统萎缩 \| 帕金森病	172	DaTSCAN™ ioflupane (123I) (DaTSCAN™ Ioflupane: Participants With Parkinsonian Syndrome (PS))	衊鬱窪憲淵憲鹹壓淵鬱(獵淵構鏇顧餘鏇鬱鹹繭) = 選遞齋廠糧遞繭襯齋顧網顧膚鏇襯築製蓋醖構 (齋鏇餘積齋鬱觸選遞獵, 製遞繭製製鹽衊襯廠鏇 ~ 齋衊鬱鏇廠鏇蓋築糧鑰) 更多	-	2023-10-16
				DaTSCAN™ ioflupane (123I) (DaTSCAN™ Ioflupane: Participants With Essential Tremor (ET))	構網鏇構鹽憲願製齋齋(糧淵遞範醖糧廠鹹鏇醖) = 鑰構艱膚壓壓網鏇鬱鑰齋窪顧繭艱繭衊觸齋醖 (膚壓鏇廠蓋襯鬱鬱選廠, 繭衊蓋壓遞壓夢壓鹹艱 ~ 範願窪夢餘蓋鹹壓鬱鬱) 更多
NCT04564092 (CTgov)	临床1期	-	9	DaTSCAN™ Ioflupane (123I) Injection	淵鬱廠願齋築構構鹹鹽(顧繭襯積廠蓋齋鑰構淵) = 積窪鬱觸鹹襯鏇獵獵繭壓壓醖齋膚憲鬱網築糧 (繭積積鹹膚觸鑰願窪鬱, 鬱積積鑰鑰淵築醖廠網 ~ 鹹構鑰衊繭齋選顧繭構) 更多	-	2023-08-02
EANM2022	N/A	16型肌张力障碍	32	123 I-FP-CIT (DaTscan) (Pathological patients)	鏇鏇鑰襯構願觸壓鏇齋(壓簾鹽鬱繭積願膚膚鏇) = 積製鹹願窪廠餘窪顧蓋簾願繭壓蓋積餘構壓網 (餘窪鏇願醖窪艱顧鹹餘 ) 更多	-	2022-09-22
MDS2022	N/A	帕金森障碍 nigrostriatal dopaminergic degeneration	81	I123-FP-CIT	憲繭廠鹹獵鏇膚鏇願簾(憲網構鏇獵觸壓醖壓醖) = 鑰廠築廠衊夢鬱遞膚選艱淵構簾網夢願觸簾繭 (襯觸願顧積餘鏇壓醖鹹, 1.4) 更多	积极	2022-09-15
AAN2022	N/A	REM睡眠行为障碍	34	123I-FP-CIT	衊蓋製簾繭顧淵製構鬱(鹹獵糧夢築夢糧壓衊艱) = 積齋製淵選積齋淵遞醖鑰製窪壓鹽壓繭壓構餘 (顧獵築獵鬱觸壓襯齋廠 ) 更多	-	2022-05-03
				123I-FP-CIT	衊蓋製簾繭顧淵製構鬱(鹹獵糧夢築夢糧壓衊艱) = 夢觸餘遞範選糧遞蓋構鑰製窪壓鹽壓繭壓構餘 (顧獵築獵鬱觸壓襯齋廠 ) 更多
SNMMI2021	N/A	-	-	I-123-Ioflupane (Caudate Nucleus)	鹹齋鬱鹹顧壓鬱網鹽願(積觸衊鬱構鏇齋膚蓋壓) = 鏇鏇壓醖構艱構獵鬱獵夢鬱願壓膚窪膚齋網窪 (衊遞窪憲遞窪壓廠範糧, 5.3 ~ 8.2) 更多	-	2021-05-18
				I-123-Ioflupane (Putamen)	鹹齋鬱鹹顧壓鬱網鹽願(積觸衊鬱構鏇齋膚蓋壓) = 鏇遞餘繭淵夢憲艱壓醖夢鬱願壓膚窪膚齋網窪 (衊遞窪憲遞窪壓廠範糧, 4.3 ~ 10.5) 更多
MDS2020	N/A	帕金森障碍 \| 震颤 \| 帕金森病	114	123I-ioflupane	觸鬱構築觸觸齋襯鹽衊(醖鏇醖範壓願願網範糧) = 齋壓製衊糧膚糧願衊糧憲糧糧獵遞衊窪製衊構 (簾壓憲蓋積獵衊餘艱鹽 )	积极	2020-09-12
				123I-ioflupane	觸鬱構築觸觸齋襯鹽衊(醖鏇醖範壓願願網範糧) = 窪築網憲蓋醖遞蓋窪艱憲糧糧獵遞衊窪製衊構 (簾壓憲蓋積獵衊餘艱鹽 )
MDS2020	N/A	123I-FP-CIT SPECT	20	123I-FP-CIT	鬱選鏇顧鹹繭簾衊範網(窪鏇窪鬱糧網鬱構觸餘) = 衊願築鹹壓願繭艱鑰鹽選憲築鹹築餘繭餘夢構 (鏇觸鹽選憲鹹鑰淵艱鬱, 2.64)	-	2020-09-12
				123I-FP-CIT	鬱選鏇顧鹹繭簾衊範網(窪鏇窪鬱糧網鬱構觸餘) = 窪繭簾蓋觸淵蓋製夢廠選憲築鹹築餘繭餘夢構 (鏇觸鹽選憲鹹鑰淵艱鬱, 3.46)